



# Pharma R&D Annual Review 2024 Infographic

Insights from our annual review of trends in pharmaceutical R&D




## Key Findings

The temporary freeze brought on by the COVID-19 pandemic is well and truly over, as 2023 saw a new high in the number of drugs in development. However, while there are signs the industry is continuing to grow, the forecast is decidedly mixed when looking at how many of these drugs reach later stages of development and emerge from the pipeline.

### Total R&D pipeline size by year

As of January 2024, Pharmaprojects recorded 22,825 drugs in development, an increase of 7.20% over 2023's figure of 21,292. This is right on trend with the five-year average increase of 7.14%.

TOTAL R&D PIPELINE SIZE BY YEAR, 2020-24




Source: Pharmaprojects®, January 2024

### Pipeline by development phase

Even as overall pipeline numbers increase, the number of drugs advancing to Phase III clinical trials appears to be slowing down. The number of candidates in Phase III rose only 1.5% from 2023 to 2024. Things were sunnier in terms of drugs emerging from the pipeline, with registered drugs up 28.9% and launches rising 9.9%.

PIPELINE BY DEVELOPMENT PHASE, 2024 VS. 2023




(N/A = not applicable and is applied to companion diagnostics prelaunch)

Source: Pharmaprojects®, January 2024

### Distribution of R&D companies by HQ country/region

The number of companies involved in pharma R&D that are headquartered in the US dipped from 43% in 2023 to 39% in 2024. Meanwhile, China continues to gather strength, with the proportion of China-based firms involved in pharma R&D rising to 16% in 2024 from 13% in 2023.



Source: Pharmaprojects®, January 2024

### Top 10 pharma companies by size of pipeline

Acquisitions helped boost the pipeline rankings of several of the top 10 companies in 2024, including Pfizer, Eli Lilly, and AstraZeneca. Novartis slipped from second to sixth due to a pipeline trim, and Jiangsu Hengrui Pharmaceuticals became the first China-based company ever to enter the top 10 thanks to its 38.7% pipeline growth.

TOP 10 PHARMA COMPANIES BY SIZE OF PIPELINE


POSITION 2024 (2023)	COMPANY	NO. OF DRUGS IN PIPELINE 2024 (2023)
1 (1)	Roche	218 (194)
2 (5)	Pfizer	205 (171)
3 (7)	AstraZeneca	166 (155)
4 (10)	Eli Lilly	159 (135)
5 (4)	Bristol Myers Squibb	158 (175)
6 (2)	Novartis	154 (191)
7 (6)	Johnson & Johnson	150 (156)
8 (13)	Jiangsu Hengrui Pharmaceuticals	147 (106)
9 (8)	Merck & Co.	145 (151)
10 (9)	Sanofi	142 (145)

Source: Pharmaprojects®, January 2024

### Top 10 R&D pipeline by therapeutic area

While oncology drugs continue to grow and remain at the top of therapeutic categories in development, alimentary/metabolic drugs came on particularly strong in 2024, posting 13.1% pipeline growth. By contrast, growth in anti-infective drugs has almost completely stalled, posting only an 0.8% increase.

PIPELINE BY DEVELOPMENT PHASE, 2024 VS. 2023



Source: Pharmaprojects®, January 2024